CRISPR Gene Editing Market Report 2025

This CRISPR Gene Editing market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The CRISPR gene editing market size has grown exponentially in recent years. It will grow from $2.26 billion in 2024 to $2.88 billion in 2025 at a compound annual growth rate (CAGR) of 27.4%. The growth in the historic period can be attributed to increased demand for genome editing technologies, rise in government funding, increased cancer cases, increased prevalence of chronic diseases, increased awareness about CRISPR technology, rise healthcare infrastructure.

The CRISPR gene editing market size is expected to see exponential growth in the next few years. It will grow to $7.51 billion in 2029 at a compound annual growth rate (CAGR) of 27.1%. The growth in the forecast period can be attributed to increasing prevalence of genetic disorders, growing emphasis on precision medicine, rising investment in CRISPR research and development, increasing geriatric population, growing prominence for the gene therapy procedures. Major trends in the forecast period include advancements in gene editing technology, expansion in the number of research studies, drug discovery and development, innovation in delivery methods, adoption of CRISPR-edited agriculture.

The rising prevalence of genetic disorders is expected to drive the growth of the CRISPR gene editing market in the coming years. Genetic disorders are health conditions caused by abnormalities in the genome, which can result from mutations in a single gene (monogenic), multiple genes (polygenic), or chromosomal abnormalities. The increasing incidence of these disorders is due to factors such as genetic mutations, aging populations, and consanguineous marriages. CRISPR gene editing plays a crucial role in managing genetic disorders by enabling precise and targeted modifications to DNA. Scientists use CRISPR to identify and correct specific mutations, restore normal gene function, and alleviate symptoms in conditions like cystic fibrosis and sickle cell anemia. For example, in July 2022, the Cystic Fibrosis (CF) Foundation, a US-based non-profit organization, reported a rise in cystic fibrosis cases, with nearly 40,000 children and adults in the United States affected in 2022, and over 105,000 people diagnosed worldwide. Therefore, the increasing prevalence of genetic disorders is driving the growth of the CRISPR gene editing market.

Major companies in the CRISPR gene editing market are focusing on developing innovative products, such as gene therapy, to expand their customer base, increase sales, and boost revenue. Gene therapy is a medical approach that uses genes to treat, prevent, or cure diseases and disorders. For example, in December 2023, the US Food and Drug Administration (FDA) approved Casgevy, a cell-based gene therapy for treating sickle cell disease. Casgevy employs CRISPR/Cas9 technology to modify hematopoietic stem cells, offering a promising treatment option for this genetic disorder.

In January 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, entered a four-year research collaboration with Beam Therapeutics. This collaboration focuses on three programs targeting rare genetic diseases affecting the liver, muscles, and central nervous system, leveraging CRISPR gene editing technology. Beam Therapeutics is a US-based biotechnology company specializing in CRISPR gene editing.

Major companies operating in the CRISPR gene editing market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., GenScript, Integrated DNA Technologies Inc., Takara Bio Inc., OriGene Technologies Inc., Intellia Therapeutics Inc., New England Biolabs, Synthego, Arbor Biotechnologies Inc., Rockland Immunochemicals Inc., Cellectis, Editas Medicine, Caribou Biosciences Inc., System Biosciences LLC, Applied StemCell, Addgene, Mirus Bio LLC, Excision BioTherapeutics Inc., GeneCopoeia Inc., ToolGen Inc., Cellecta Inc., CRISPR Therapeutics, ERS Genomics Limited.

North America was the largest region in the CRISPR gene editing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the CRISPR gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the CRISPR gene editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Clustered regularly interspaced short palindromic repeats (CRISPR) gene editing stands as a groundbreaking biotechnological tool that enables precise modifications to the DNA of living organisms. This technology harnesses a natural defense mechanism found in bacteria, where CRISPR sequences in DNA are utilized to identify and cut specific genetic sequences. CRISPR gene editing empowers scientists to add, remove, or alter genetic material with remarkable precision, making it a potent technique for research, therapeutic interventions, and potential treatments for genetic disorders.

The primary types of CRISPR gene editing encompass CRISPR-associated nuclease (Cas nuclease), guide RNA, DNA ligase, restriction endonuclease, and other related components. CRISPR-associated nuclease, commonly known as Cas nuclease, functions as molecular scissors, cleaving targeted DNA sequences as directed by CRISPR. This aspect focuses on the development and utilization of Cas proteins for precise gene editing, offering promising applications across industries such as agriculture, medicine, and biotechnology. It offers diverse services including design tools, plasmids, CRISPR-associated protein 9 (Cas9) and guide RNA (gRNA), delivery systems, and more. Additionally, it encompasses various technologies such as CRISPR/Cas9, zinc finger nucleases, and others, serving applications such as agriculture, biomedical research, industrial processes, genome engineering, disease modeling, functional genomics, and more. These solutions cater to a range of end users including academic institutions, research centers, biotech firms, contract research organizations (CROs), pharmaceutical companies, and biopharmaceutical companies.

The CRISPR gene editing market research report is one of a series of new reports that provides CRISPR gene editing market statistics, including the CRISPR gene editing industry global market size, regional shares, competitors with CRISPR gene editing market share, detailed CRISPR gene editing market segments, market trends, and opportunities, and any further data you may need to thrive in the CRISPR gene editing industry. These CRISPR gene editing market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The CRISPR gene editing market includes of revenues earned by entities by providing services such as gRNA design and vector construction, cell line and engineering, screening services, drug development services, and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR gene editing market also includes sales of gene editing vectors, laboratory equipment, kits and enzymes, libraries, design tools, antibodies, bioinformatics tools, and cell culture equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.